Plasma carnitine, choline, γ-butyrobetaine, and trimethylamine-N-oxide, but not zonulin, are reduced in overweight/obese patients with pre/diabetes or impaired glycemia
Background and aims Zonulin, carnitine, choline, γ-butyrobetaine (γ-BB), and trimethylamine-N-oxide (TMAO) are intricately involved in metabolic anomalies and type 2 diabetes mellitus (T2D). This study aimed to compare and correlate the plasma levels of zonulin, carnitine, choline, γ-butyrobetaine, and TMAO, along with the adiposity, atherogenicity, surrogate insulin resistance (sIR), and proinflammatory hematological indices of newly diagnosed drug-naive prediabetic and diabetic patients vs. apparently healthy normoglycemic controls. Methods In a cross-sectional study, 30 normoglycemic subjects (controls) and 16 prediabetic (preDM) and 14 type 2 diabetes (T2D) cases, that were gender and age-matched, were enrolled. Zonulin, carnitine, choline, γ-BB, and TMAO plasma levels were appraised using colorimetric assays. A comparison between the study groups was conducted by ANOVA while Spearman rank correlations between the metabolic risk biomarkers and between the risk markers and adiposity, sIR, atherogenicity, and proinflammatory hematological indices were also examined. Results Significant intergroup discrepancies in plasma carnitine, choline, γ-BB, and TMAO (but not zonulin) could be recognized in the cases vs. controls. Fasting blood glucose (FPG), glycated hemoglobin (A1C), triglycerides (TGs), body mass index (BMI), lipid accumulation product (LAP), visceral adiposity index (VAI), atherogenic index of plasma (AIP), and all sIR were outstandingly higher in the cases vs. controls. Blood indices lacked a scoring value to discriminate cases from controls. Inadvertently, no relation was found between plasma carnitine, choline, γ-BB, TMAO, or zonulin in cases. Among the rest of the markers and sIR indices, the triglyceride glucose-body mass index (TyG*BMI) related reciprocally to zonulin. Noticeably, among adiposity indices, TyG*BMI, triglyceride glucose-waist circumference (TyG*WC), and metabolic score for insulin resistance (MetS-IR) positively associated with waist circumference (WC), hip circumference (HC), BMI, body adiposity index (BAI), and waist-to-height ratio (WHtR). Exceptionally, LAP proportionally correlated with all sIR. TyG*WC and MetS-IR correlated directly with the conicity index (CI). WHR directly associated with triglyceride glucose (TyG) index and TyG*WC. Remarkably, the TyG index (but not TyG*BMI, TyG*WC, or MetS-IR) positively associated with all atherogenicity indices and RDW (but none of other blood indices). TMAO correlated inversely (p < 0.05) and moderately with choline. Distinctively, carnitine associated negatively with TC (p < 0.05). Both choline and carnitine related similarly and directly with PLR but inversely with lymphocytes (p<.05). Effectively, γ-butyrobetaine associated with both WC and the TyG-WC index equally negatively (p < 0.05). Substantially, γ-butyrobetaine correlated inversely with both atherogenic LDL-C/HDL-C ratio and MPV (p < 0.05). No pronounced relations were detected between the five microbiome signature determinants and glycemic control parameters (FBG and A1C%), sIR (TyG, TyG-BMI, or MetS-IR), adiposity (WHR, WHtR, CI, BAI, LAP, or VAI), atherogenicity indices (TC/HDL-C ratio, non-HDL-C/HDL-C ratio, or AIP), or blood indices (NLR or MLR). Conclusion Given the intergroup discrepancies in sIR, plasma zonulin, carnitine, choline, γ-BB, and TMAO along with their elective correlations with indices and clinical parameters of metabolic dysregulations, our study cannot rule out any possible molecular crosstalk and interplay of the biomarkers studied with the pathophysiology of prediabetes/diabetes. All in all, plasma zonulin, carnitine, choline, γ-BB, and TMAO with sIR can be putative surrogates for molecular cardiometabolic risk biomarkers to use as prognostic/predictive tools for the diagnosis/prevention and potential targets for prediabetes/diabetes management modalities..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
International journal of diabetes in developing countries - 43(2022), 4 vom: 14. Juni, Seite 592-605 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Snouper, Alia [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
γ-Butyrobetaine (γ-BB) |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2022 |
|---|
| doi: |
10.1007/s13410-022-01088-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144738661 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144738661 | ||
| 003 | DE-627 | ||
| 005 | 20240118100625.0 | ||
| 007 | tu | ||
| 008 | 240118s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13410-022-01088-x |2 doi | |
| 035 | |a (DE-627)OLC2144738661 | ||
| 035 | |a (DE-He213)s13410-022-01088-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Snouper, Alia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma carnitine, choline, γ-butyrobetaine, and trimethylamine-N-oxide, but not zonulin, are reduced in overweight/obese patients with pre/diabetes or impaired glycemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2022 | ||
| 520 | |a Background and aims Zonulin, carnitine, choline, γ-butyrobetaine (γ-BB), and trimethylamine-N-oxide (TMAO) are intricately involved in metabolic anomalies and type 2 diabetes mellitus (T2D). This study aimed to compare and correlate the plasma levels of zonulin, carnitine, choline, γ-butyrobetaine, and TMAO, along with the adiposity, atherogenicity, surrogate insulin resistance (sIR), and proinflammatory hematological indices of newly diagnosed drug-naive prediabetic and diabetic patients vs. apparently healthy normoglycemic controls. Methods In a cross-sectional study, 30 normoglycemic subjects (controls) and 16 prediabetic (preDM) and 14 type 2 diabetes (T2D) cases, that were gender and age-matched, were enrolled. Zonulin, carnitine, choline, γ-BB, and TMAO plasma levels were appraised using colorimetric assays. A comparison between the study groups was conducted by ANOVA while Spearman rank correlations between the metabolic risk biomarkers and between the risk markers and adiposity, sIR, atherogenicity, and proinflammatory hematological indices were also examined. Results Significant intergroup discrepancies in plasma carnitine, choline, γ-BB, and TMAO (but not zonulin) could be recognized in the cases vs. controls. Fasting blood glucose (FPG), glycated hemoglobin (A1C), triglycerides (TGs), body mass index (BMI), lipid accumulation product (LAP), visceral adiposity index (VAI), atherogenic index of plasma (AIP), and all sIR were outstandingly higher in the cases vs. controls. Blood indices lacked a scoring value to discriminate cases from controls. Inadvertently, no relation was found between plasma carnitine, choline, γ-BB, TMAO, or zonulin in cases. Among the rest of the markers and sIR indices, the triglyceride glucose-body mass index (TyG*BMI) related reciprocally to zonulin. Noticeably, among adiposity indices, TyG*BMI, triglyceride glucose-waist circumference (TyG*WC), and metabolic score for insulin resistance (MetS-IR) positively associated with waist circumference (WC), hip circumference (HC), BMI, body adiposity index (BAI), and waist-to-height ratio (WHtR). Exceptionally, LAP proportionally correlated with all sIR. TyG*WC and MetS-IR correlated directly with the conicity index (CI). WHR directly associated with triglyceride glucose (TyG) index and TyG*WC. Remarkably, the TyG index (but not TyG*BMI, TyG*WC, or MetS-IR) positively associated with all atherogenicity indices and RDW (but none of other blood indices). TMAO correlated inversely (p < 0.05) and moderately with choline. Distinctively, carnitine associated negatively with TC (p < 0.05). Both choline and carnitine related similarly and directly with PLR but inversely with lymphocytes (p<.05). Effectively, γ-butyrobetaine associated with both WC and the TyG-WC index equally negatively (p < 0.05). Substantially, γ-butyrobetaine correlated inversely with both atherogenic LDL-C/HDL-C ratio and MPV (p < 0.05). No pronounced relations were detected between the five microbiome signature determinants and glycemic control parameters (FBG and A1C%), sIR (TyG, TyG-BMI, or MetS-IR), adiposity (WHR, WHtR, CI, BAI, LAP, or VAI), atherogenicity indices (TC/HDL-C ratio, non-HDL-C/HDL-C ratio, or AIP), or blood indices (NLR or MLR). Conclusion Given the intergroup discrepancies in sIR, plasma zonulin, carnitine, choline, γ-BB, and TMAO along with their elective correlations with indices and clinical parameters of metabolic dysregulations, our study cannot rule out any possible molecular crosstalk and interplay of the biomarkers studied with the pathophysiology of prediabetes/diabetes. All in all, plasma zonulin, carnitine, choline, γ-BB, and TMAO with sIR can be putative surrogates for molecular cardiometabolic risk biomarkers to use as prognostic/predictive tools for the diagnosis/prevention and potential targets for prediabetes/diabetes management modalities. | ||
| 650 | 4 | |a Zonulin trimethylamine-N-oxide | |
| 650 | 4 | |a Choline | |
| 650 | 4 | |a Carnitine | |
| 650 | 4 | |a γ-Butyrobetaine (γ-BB) | |
| 650 | 4 | |a Trimethylamine-N-oxide (TMAO) | |
| 650 | 4 | |a Flavin monooxygenase 3 | |
| 650 | 4 | |a Atherogenic index of plasma | |
| 650 | 4 | |a Intestinal barrier integrity | |
| 650 | 4 | |a Metabolomics | |
| 700 | 1 | |a Kasabri, Violet |0 (orcid)0000-0003-1927-0193 |4 aut | |
| 700 | 1 | |a Bulatova, Nailya |4 aut | |
| 700 | 1 | |a Suyagh, Maysa |4 aut | |
| 700 | 1 | |a Sadder, Monther |4 aut | |
| 700 | 1 | |a Shnewer, Khaldoun |4 aut | |
| 700 | 1 | |a Yousef, Ismail |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of diabetes in developing countries |d Springer India, 2006 |g 43(2022), 4 vom: 14. Juni, Seite 592-605 |w (DE-627)767568591 |w (DE-600)2732590-8 |w (DE-576)393437949 |x 0973-3930 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:4 |g day:14 |g month:06 |g pages:592-605 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s13410-022-01088-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 4 |b 14 |c 06 |h 592-605 | ||